Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTO-1310 in Healthy Volunteers, Atopic Dermatitis, and Chronic Pruritus
NCT06787586Phase 1Completed
- Sponsor
- Attovia Therapeutics
- Start
- Jan 2025
- Primary completion
- Jun 2026
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of ATTO-1310 in atopic dermatitis (AD) and chronic pruritus (CP) (6 arms), sponsored by Attovia Therapeutics. Primary endpoints: Incidence of Adverse Events at 143 days, Incidence of laboratory abnormalities at 143 days and 2 more. Started Jan 2025; status: completed.
02
Drugs
ATTO-1310
03
Conditions
atopic dermatitis (AD)chronic pruritus (CP)
Beyond the preview
Go deeper on NCT06787586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06787586.